These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36693228)

  • 1. Systemic Therapy Update on
    Garje R; Hope TA; Rumble RB; Parikh RA;
    JCO Oncol Pract; 2023 Mar; 19(3):132-135. PubMed ID: 36693228
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic Therapy Update on
    Garje R; Rumble RB; Parikh RA
    J Clin Oncol; 2022 Nov; 40(31):3664-3666. PubMed ID: 36112960
    [No Abstract]   [Full Text] [Related]  

  • 3. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New drugs approval: Lutetium-PSMA in metastatic castration-resistant prostate cancer].
    Roulleaux Dugage M; Schlürmann F
    Bull Cancer; 2023 Jun; 110(6):600-602. PubMed ID: 37059642
    [No Abstract]   [Full Text] [Related]  

  • 5. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exceptional 4-year response to
    Gafita A; Wang H; Tauber R; D'Alessandria C; Weber WA; Eiber M
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2212-2213. PubMed ID: 31273434
    [No Abstract]   [Full Text] [Related]  

  • 7. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
    Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
    Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Hadaschik B; Herrmann K
    Eur Urol; 2021 Oct; 80(4):520-521. PubMed ID: 34312019
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
    Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
    Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Zang J; Liu Q; Sui H; Wang R; Jacobson O; Fan X; Zhu Z; Chen X
    J Nucl Med; 2020 Dec; 61(12):1772-1778. PubMed ID: 32358086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
    Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
    Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
    Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
    [No Abstract]   [Full Text] [Related]  

  • 15. Radioligand Therapy With
    Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
    AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4-6.
    Ardolino LC; Dear R; Armstrong AJ; Gillessen S; Joshua AM
    Eur Urol; 2023 Oct; 84(4):e94-e95. PubMed ID: 37355357
    [No Abstract]   [Full Text] [Related]  

  • 17. Early Prostate-Specific Antigen Changes and Clinical Outcome After
    Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
    J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.
    Keam SJ
    Mol Diagn Ther; 2022 Jul; 26(4):467-475. PubMed ID: 35553387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.
    Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO
    Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetry of
    Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.